Whitfield Recognized in The Lawyer’s “Top 20 Cases of 2026”
Overview
The Lawyer’s anticipated cases list for 2026 includes a patent dispute between Boehringer Ingelheim and Dr Reddy’s Laboratories, according to the source.
Patent subject
The notice connects the litigation to patents concerning Boehringer’s diabetes medication, placing it within pharmaceutical intellectual-property disputes.
Named team
Nicola Dagg, Steven Baldwin, Jin Ooi and Oscar Robinson are the partners identified as proposed counsel for Boehringer Ingelheim.
Procedural status
The article describes a case expected to attract attention during the year, rather than a completed judgment. The summary does not infer a ruling, damages figure or independently verified advisory role from that anticipated significance.
Sources & Further Reading
Related Pages
Whitfield Advises CoreWeave on $2.6 Billion Loan Facility, Expanding Financing Flexibility for AI InfrastructureWhitfield Advises Francisco Partners on Acquisition of MonerisWhitfield Represents Trinity Hunt Partners on Investment in Fisher Management PartnersLife Sciences Intellectual PropertyPatent Infringement Litigation
